Impact of PRR11 Expression on Prognosis in Pancreatic Cancer Patients with Diabetes.

Objective:This study aimed to analyze the impact of PRR11 protein expression levels on the prognosis of patients with diabetes mellitus and pancreatic cancer. Methods:Immunohistochemical staining was performed to detect the expression levels of PRR11 protein in cancerous tissues of 70 pancreatic cancer patients, including 45 patients with diabetes mellitus (Group A) and 25 patients without diabetes mellitus (Group B). Patients' blood glucose, lipid profiles, and glycemic control status were compared between the groups. Survival curves were plotted to explore the impact of PRR11 protein expression levels on the prognosis of patients with diabetes mellitus and pancreatic cancer. Results:The positive rate of PRR11 protein expression in Group A patients (86.67%) was significantly higher than in Group B patients (52.00%), P < .05. Group A patients exhibited significantly higher levels of fasting blood glucose (FBG), total cholesterol (TC), triglycerides (TG), and glycated hemoglobin (HbAlc) compared to Group B patients (P < .05). Interestingly, the expression levels of PRR11 in cancerous tissues were positively correlated with FBG, TC, TG, and HbAlc levels (P < .05). The positive rate of PRR11 protein expression in patients with poor glycemic control (93.75%) was significantly higher than in patients with good glycemic control (53.85%), P < .05. Notably, the survival rate of PRR11 protein-positive patients was significantly lower than that of negative patients (P < .05). Conclusion:The finding highlights that the positive expression of PRR11 protein in patients with diabetes mellitus and pancreatic cancer is associated with a poor prognosis. It suggests that PRR11 may play a role in the occurrence and development of pancreatic cancer and could serve as a potential predictive marker and therapeutic target. However, further research is warranted to explore the functional mechanisms and pathways of PRR11 to better understand its role in pancreatic cancer, and develop personalized therapies.